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Background: The use of antibiotic drugs triggers a complex interaction involving many 
biological, sociological, and psychological determinants. Resistance to antibiotics is a serious 
worldwide problem which is increasing and has implications for morbidity, mortality, and health 
care both in hospitals and in the community.
Objectives: To analyze current research on the determinants of antibiotic resistance and com-
prehensively review the main factors in the process of resistance in order to aid our understanding 
and assessment of this problem.
Methods: We conducted a MedLine search using the key words “determinants”, “antibiotic”, 
and “antibiotic resistance” to identify publications between 1995 and 2007 on the determinants 
of antibiotic resistance. Publications that did not address the determinants of antibiotic resistance 
were excluded.
Results: The process and determinants of antibiotic resistance are described, beginning with 
the development of antibiotics, resistance and the mechanisms of resistance, sociocultural 
determinants of resistance, the consequences of antibiotic resistance, and alternative measures 
proposed to combat antibiotic resistance.
Conclusions: Analysis of the published literature identiﬁ  ed the main determinants of antibiotic 
resistance as irrational use of antibiotics in humans and animal species, insufﬁ  cient patient educa-
tion when antibiotics are prescribed, lack of guidelines for treatment and control of infections, 
lack of scientiﬁ  c information for physicians on the rational use of antibiotics, and lack of ofﬁ  cial 
government policy on the rational use of antibiotics in public and private hospitals.
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Introduction
Resistance to a variety of antibiotics is an important phenomenon that has been the 
subject of many scientiﬁ  c meetings during the past decade. Resistance has become a 
serious public health problem around the world and there are no indications that it is 
abating. It includes pathogenic agents that utilize different mechanisms and channels 
of drug resistance in different countries.1,2
Recent debate on the problem has focused on the inappropriate use of antibiotics 
worldwide.2,3 This practice fosters conditions that favor multiplication of resistant 
microorganisms while at the same time suppressing susceptible forms.4 Antibiotic 
resistance can represent an enormous cost to a patient and to the health care system. 
When the appropriate antibiotic is not applied, the process of infection is not interrupted, 
which can lead to serious consequences.5,6
Resistance can arise from the use of antibiotics, antimalarial drugs, and pesticides. 
Each beneﬁ  cial application of these treatments increases the likelihood that they will 
be less effective both for the intended target and for other targets when used in the 
future. In this way the use of these drugs triggers a complex interaction involving 
many biological, sociological, and psychological determinants.7,8Infection and Drug Resistance 2009:2 2
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At least three interdependent variables are involved in 
antibiotic overuse. Patients expect to be prescribed antibiotics 
for any infection, often simply for any febrile condition. 
Physicians, for their part, fear uncontrolled infection. 
Antibiotics provide a false sense of security when they are 
prescribed before or without undertaking a complete diagnosis. 
Thirdly, many countries allow antibiotics to be purchased 
over the counter without a medical prescription.9
Differences in location, population demographics, and 
ofﬁ  ce police towards pharmaceutical representatives and 
sampling are also potentially important covariates for the 
overuse of antibiotics. Two studies in Mexico found that 
self-medication of Rx drugs accounted for 42% of all the 
Rx consumed during the studies period and antibiotic alone 
accounted for 20.1%.10,11
Access to cheaper or free antibiotic agents, like generic 
drugs, has been also associated with overuse of antibiotic 
especially in the developing countries as well as promotion 
of free generic antibiotic samples in developed countries.12 
Recently, Conklin and colleagues acknowledge that many 
infections, including acute upper respiratory tract infections 
do not require initiation of any antibiotic therapy, and that the 
convenient presence of some type of promotion like “kiosks” 
could potentially have promoted the overuse of antibiotics 
for clinically inappropriate indications.13–15
During the past 10 to 15 years, antibiotic-resistant organ-
isms have increased steadily, and currently represent a threat 
to the treatment of illness, to the point where no antibiotics 
are available to treat some life-threatening infections.16–18 
An increase in research on infection control and interven-
tions to improve patient safety can be expected during the 
coming 20 years.19
The use of antibiotics to treat bacterial illnesses in ani-
mals and plants increased throughout the twentieth century. 
For example, antibiotics became an important element in 
commercial animal production for their favorable effect on 
growth when added to feed in subtherapeutic quantities.20
We all share the blame for the development of antibiotic 
resistance, including governments, universities, professional 
associations, the pharmaceutical and chemical industries, 
health care professionals, and consumers, who regard drugs 
as a quick and easy answer to conditions that actually require 
in-depth responses from individuals and society.3 Although 
resistance has been developing gradually over many years, 
it seems inexplicable that the medical community has not 
acted earlier.
The purpose of our review was to analyze the current 
situation on the determinants of antibiotic resistance, and 
comprehensively review the main factors in the process of 
resistance in order to improve the understanding of this issue.
Methods
We conducted a MedLine search using the key words 
“determinants”, “antibiotic”, and “antibiotic resistance” to 
identify publications between 1995 and 2007 on the determi-
nants of antibiotic resistance. Publications that did not address 
the determinants of antibiotic resistance were excluded.
Results
The process and determinants of antibiotic resistance can be 
described as follows:
Discovery and development 
of antibiotics
Antibiotics are among the most important achievements of 
the twentieth century. Although some effective treatments 
used long ago contained antibiotic chemicals, their use in 
general was limited to certain illnesses.
Antibiotics are deﬁ  ned as substances produced by micro-
organisms (bacteria, fungi, actinomycetes), which suppress 
the proliferation of other (pathogenic) microorganisms and 
can eventually destroy these. The term “antibiotics” now 
includes synthetic antibacterials such as the sulfonamides and 
quinolones, which are not actually synthesized by microbes. 
Different antibiotics have quite different physical, chemical, 
and pharmacological properties, as well as different antibac-
terial spectra and mechanisms of action.21
Early in the twentieth century, infectious and parasitic 
diseases were the major causes of human morbidity and 
mortality, especially among infants and children.22 The golden 
age of antibiotic treatments was ushered in by the discovery 
and subsequent development of penicillin from the ﬁ  ltrate of 
a fungus Penicillium notatum culture by Alexander Fleming 
in 1929. Another key development in the modern history of 
antibiotics was the synthesis in 1935 by Gerhard Domagk 
of the ﬁ  rst sulfonamide, prontosil, which was spectacularly 
effective against streptococcus infections.5,17,23–30
The success of these two antibiotics stimulated a search 
for further antibiotic substances. In 1944, the work of Selman 
Waksman in a soil microbiology laboratory led to the isolation 
of streptomycin from a soil actinobacterium. Streptomycin 
was the first antibiotic remedy against Mycobacterium 
tuberculosis, the main cause of tuberculosis, as well as many 
Gram-negative bacteria. Since that time, a great quantity of 
research, much of it undertaken by pharmaceutical companies, 
has yielded many useful drugs.9,31Infection and Drug Resistance 2009:2 3
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During the past 20 years, approval of new antibiotics 
has decreased. Some 50 antibiotics have been developed, 
and large pharmaceutical companies have provided ever-
improved new generations of antibiotics. At the same time, 
the importance of infectious diseases in public health has 
decreased, and pharmaceutical research has focused increas-
ingly on treatments for chronic diseases.5,32
The fundamental predicament is that antibiotics are a 
nonrenewable source, because the length of time they are 
beneﬁ  cial and available appears to have a biological limit, 
something which is not the case with other treatments. Few 
antibiotics and/or antifungals are currently being developed, 
in comparison with investment in research and development 
of antivirals.6
The main reason that the industry has moved away from 
antibiotic research and development is that the investment can 
no longer be recovered rapidly, partly because of increased 
regulatory conditions and strict price controls imposed by 
many governments.17,20,33
The useful lifetime of current and future antibiotics could 
depend on the speed with which resistance develops, which 
in turn depends on the usage model, not only in humans but 
also in agriculture and horticulture.34
Recent worldwide development of methicillin-resistant 
Staphylococcus aureus (MRSA) in the community has stimu-
lated the development of new antibiotics. The new develop-
ments of antibiotic are summarized in Table 1 as well as the 
new agent brand names and active principle, antibiotic class, 
antimicrobial activity, country, and date of approval.
Resistance to teicoplanin (Targocid®), a ﬁ  rst-generation 
glycopeptide, has emerged because of its similarity to other 
glycopeptides, which has motivated research aimed at 
developing new antibiotics.35,36
Streptogramins are a combination of quinupristin and 
dalfopristin (Synercid®). An oral streptogramin, pristinamycin 
in combination with doxycycline, is used in Europe to treat 
MRSA infections but is not available in the US.33,35,37,38
Second-generation glycopeptides are dalbavancin, 
telavancin, and oritavancin. The use of these drugs should 
be limited to treatment of Gram-positive multidrug-
resistant bacterial infections.33,35,38–40 Telavancin was 
superior to standard therapy for microbiologic eradica-
tion in patients with S. aureus infection (92% versus 78%) 
and in patients with MRSA. Currently, telavancin is under 
investigation (phase II).41
Daptomycin (Cubicin®) has been shown to be effective 
in the treatment of skin and soft tissue infections, and 
bacteremia with right-sided endocarditis, but efﬁ  cacy has 
not been demonstrated for pneumonia as a result of binding 
with pulmonary surfactants.33,35,42
Tigecycline (Tygacil®) is a bacteriostatic agent which is 
most effective in complicated skin and soft tissue infections, 
as well as hospital-acquired and community-acquired 
intra-abdominal infections.33,35,43,44
Linezolid (Zyvox®) is recommended for pneumonia caused 
by drug-resistant S. pneumoniae complicated by skin and soft 
tissue infections and for diabetic foot infections. It is indicated 
for the treatment of catheter-related bloodstream infections or 
catheter-site infections. Unfortunately, the number of reports 
of resistance and therapeutic failure associated with linezolid 
has been increasing since 2005.33,35,36,45
The Food and Drug Administration (FDA) updated the 
labeling for the antibiotic telithromycin (Ketek®) to improve 
its safe use of by patients; the changes include the removal 
of two of the three previously approved indications – acute 
bacterial sinusitis and acute bacterial exacerbations of chronic 
bronchitis – from the drug’s label. The FDA approved “a boxed 
warning” that states that telithromycin is contraindicated in 
patients with myasthenia gravis. In addition, warnings were 
strengthened for speciﬁ  c drug-related adverse events like 
visual disturbances and loss of consciousness and visual 
disturbances and hepatotoxicity. Telithromycin is marketed 
and used extensively in many other countries, including Japan 
and countries in Europe.33,35,38,46
Ertapenem (Invanz®) is recommended for complicated 
intra-abdominal infections, community acquired pneumonia, 
complicated skin and skin structure infections, complicated 
urinary tract infections including pyelonephritis. Ertapenem 
resistance has recently appeared.33,47
Doripenem (Doribax®) shows improved stability against 
beta-lactamases. The US FDA has approved new indications 
for doripenem.33,48
Faropenem in dosage form (oral only) reduced activity 
against MRSA, but is not likely to be used as a ﬁ  rst-line 
therapy for invasive, multidrug-resistant S. aureus infections. 
Faropenem medoxomil (formerly faropenenm daloxate) is 
an oral prodrug that has been evaluated as a therapy for 
community-acquired respiratory tract infections.41,49
The new antibiotic, iclaprim, is a diaminopyrimidine, 
selective dihydrofolate inhibitor. It is currently undergoing 
phase III clinical trials for treating skin and skin structure 
infections.39–41
The pharmaceutical industry still lacks strategies for 
developing novel antibiotics. Only two new classes of 
antibiotics of novel mechanisms of action (linezolid and dap-
tomycin) have been introduced into the market during the last Infection and Drug Resistance 2009:2 4
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Table 1 Development of new antibiotics during the last three decades
Antibiotic agent, brand 
and active and principal names
Antibiotic class Antimicrobial activity Country and date of approval
Quinupristin and dalfopristin 
(Synercid®) I.V.
Streptogramins Infections associated with vancomycin-
resistant Enterococcus faecium bacteremia
US, September 21, 1999.33,35,37,38
Dalbavancin, telavancin, 
oritavancin
Second-generation 
glycopeptides
Bactericidal activity against MRSA, VRSA, 
vancomycin-resistant enterococcus and 
drug-resistant Streptococcus pneumoniae
US, phase II, 2009.33,35,38-40
Daptomycin (Cubicin®) I.V. Cyclic lipopeptide 
(new class of antibiotic)
Bactericidal activity against Gram-positive 
S. aureus, MRSA, Staphylococcus epidermidis 
including methicillin-resistant S. epidermidis, 
vancomycin-resistant enterococcus, 
penicillin-resistant S. pneumoniae and 
Streptococcus pyogenes
US, December 9, 2003.33,35,42
Tigecycline (Tygacil®) I.V. Glycylcycline similar 
to the tetracyclines
Bacteriostatic activity against Gram-positive, 
Gram-negative and atypical anaerobic 
bacteria, and antibiotic-resistant, MRSA, 
vancomycin-resistant enterococcus, 
penicillin-resistant S. pneumoniae
US, June, 2005.33,35,43,44
Linezolid (Zyvox®) Oral 
and parenteral forms
Oxazolidinone Bacteriostatic activity against enterococci and 
staphylococci, bactericidal activity against many 
drug-resistant streptococci, S. pneumoniae 
and infections caused by anaerobic bacteria
US,   April 18, 2000.33,35,36,45
Telithromycin (Ketek®) Erythromycin 
derivative
The FDA announced changes, including 
the removal of two of the three previ-
ously approved indications – acute bacterial 
sinusitis and acute bacterial exacerbations 
of chronic bronchitis. Ketek is now indicated 
for the treatment of community-acquired 
pneumoniae (of mild to moderate severity) 
due to Streptococcus pneumoniae, (including 
multi-drug resistant isolates), Haemophilus 
inﬂ  uenzae, Moxarella catarrhalis, Chlamydophila 
pneumoniae, or Mycoplasma pneumoniae
US,   April 01, 2004.33,35,36,38,46 
Last published revision: 
February 12, 2007
Ertapenem (Invanz®)
I.V. a and intramuscular
Carbapenem Activity against Gram-positive and 
Gram-negative bacteria, but shows only 
limited activity against Enterococcus 
aspp., Pseudomonas aeruginosa and other 
nonfermenting Gram-positive bacteria
US, November 21, 2001.33,47
Doripenem (Doribax®) I.V. a Carbapenem Bactericidal activity, for the treatment 
of complicated urinary tract and 
intra-abdominal infections
US, October 12, 2007.33,48
Faropenem Oral Carbapenem It was developed for the treatment of 
community-acquired respiratory tract 
infections and later for uncomplicated skin 
and skin structure infections. It was shown 
to be active against penicillin-resistant 
S. pneumoniae and β-lactamase-producing 
H. inﬂ  uenzae and M. catarrhalis
Not yet FDA approved, 2008.41,49
Ceftobiprole (Zeftera®) Cephalosporine Bactericidal activity is mainly active against 
Gram-positive pathogens. For the treatment 
of complicated skin and soft tissue infections 
and nosocomial pneumonia caused by 
MRSAb, enterococci and S. pneumoniae
US, phase III, 2009.33,35,40
Iclaprim Diaminopyrimidine 
New antibiotic
It has demonstrated in vitro activity against 
S. aureus, including MRSAb. Iclaprim was also 
active against one strain of VRSAc
US, phase III, 2009.39-41
Abbreviations: IV, intravenous presentation; MRSA, methicillin-resistant S. aureus;  VRSA, vancomycin-resistant S. aureus.Infection and Drug Resistance 2009:2 5
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three decades.50,51 Many of the new antibiotics are chemical 
modiﬁ  cations of existing drugs and are rapidly overtaken 
by bacteria in the environment.35 Recently, there were new 
achievements in researching new essential bacterial genes,   
potential targets for antibacterial drugs, and application of 
metagenomics strategy.50
Antibiotic resistance
Antibiotic resistance would seem to be an inevitable 
consequence of the use of antibiotics. It was described for the 
ﬁ  rst time in the 1940s, and found in a β-lactamase-producing 
strain of S. aureus.21,52,53
The rapid development of resistance in bacteria and 
viruses is an evolutionary response to the selective pressure 
of antibiotics and results from natural selection. It is accepted 
that microbiological adaptation evolves, and that the main 
reason for the development of antibiotic resistance is the 
widespread use of antibiotics.7,29,54–58
Antibiotics have been called miracle drugs, but 60 years 
of use, underuse, and overuse have resulted in increasingly 
frequent resistance in a growing number of antibiotic-bacteria 
combinations. Resistance rates are quite variable, depending 
on context and environment.55,59–61
The first resistant strains appeared in hospitals, but 
rapidly spread to the community and are continuing to spread 
around the world. Resistant microorganisms recognize no 
geographical borders.30
Many pathogenic agents have become resistant to 
various different classes of antibiotic drugs since the 1960s. 
This fact has become clinically, epidemiologically and 
socioeconomically important, because infections caused 
by resistant microorganisms can be especially difﬁ  cult and 
costly to treat.1
Mechanisms of antibiotic resistance
The evolution of resistance falls into two categories: 
a) molecular redundancy: Organisms adapt their physiology 
to new environments after receiving a signal to change their 
physiological state. The signal usually arrives from the 
new environment. The change in physiological state occurs 
uniformly when the new environment is not lethal to the 
organism. b) Molecular inﬁ  delity: Cells under stress are more 
receptive to foreign DNA; in addition, cells under certain 
forms of stress have high mutation rates.29
Bacteria are highly adaptable organisms with a remarkable 
ability to mutate in response to their environment. Bacteria 
that survive the effects of an antibiotic are more adaptable, 
and subsequently develop resistant gene or genome mutations. 
These genetically altered bacteria multiply to produce a 
population resistant to the antibiotic, and can also transfer 
their new resistance-carrying genes to other bacterial species 
through the process of conjugation. Certain antibiotics have 
mutagenic activity, which can speed up the development of 
resistance.7,35,55–62
Multiple resistant genes which are resistant to different 
antibiotics with the same chemical structure are often found 
in the same plasmid or transposon. If the drug mechanism 
is similar, bacteria resistant to one member of the group will 
also be resistant to the others.61,63–70
Bacteria can be resistant to an antibiotic for any of several 
reasons: 1) the drug does not reach its objective; 2) the drug is 
deactivated; or 3) the target is altered. Some bacteria produce 
enzymes on the surface of the cell or within the cell, which 
inactivate the antibiotic substance, whether by hydrolysis, 
acetylation, phosphorylation or adenylation.38
Others have impermeable membranes that resist 
penetration by the drug. Bacteria lacking these ducts or 
channels may be resistant to hydrophilic antibiotics. Others 
lack the transport systems needed for the drug to penetrate 
into the bacteria.21
A recent report suggests that airborne intercellular 
communication between isolated bacterial colonies may 
induce resistance.56,71,72
Determinants of resistance
Several broad inﬂ  uences on antibiotic decision-making can 
be identiﬁ  ed, which help to explain the different resistance 
rates:6,73
• The  ﬁ  rst is the behavior of the antibiotic prescriber, that 
is, the physician, physician extender, or nurse practitioner. 
Physicians differ in their choice, use and prescribed dose 
of antibiotics.
•  The second is patient demand, according to different 
attitudes to health care.
• Thirdly,  macro-level  inﬂ  uences on prescribing antibiotics, 
include in particular, sociocultural, economic, and health 
care regulatory policy factors. Cultural factors may help 
to determine which signs and symptoms are perceived as 
abnormal, and require medical care and drug treatments. 
Health care practitioners must be persuaded that the primary 
determinant of patient satisfaction is not a prescription for 
an antibiotic, but rather effective communication about 
their illness.
•  Fourthly, some others determinants of antibiotic resis-
tance not less important are dosing variation and use of 
poor pharmacodynamic principles among others.74-77Infection and Drug Resistance 2009:2 6
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A number of Canadian and American studies have 
suggested that antibiotic prescribers may be inﬂ  uenced by such 
characteristics as where they received their medical training, 
years in practice, hospital afﬁ  liation, and type of practice 
(private or public hospital).16,72 Burke noted that inappropriate 
prophylactic use of antibiotics for surgical patients is common. 
Unwarranted, prolonged preoperational antibiotic prophylaxis 
increases resistance to antibiotic drugs.6,78 Some important 
errors include delayed antibiotic administration, excessive 
duration and the use of inappropriate agents.73 Although the 
chain of causality is not clear, selection of resistant bacteria 
has been promoted by multiple courses of antibiotics, ﬁ  rst-line 
treatment with broad spectrum antibiotics, long duration anti-
biotic treatment, and antibiotic treatment of viral infections of 
the respiratory tract. When clinicians are not sure whether an 
infection is bacterial, they tend to prescribe antibiotics. There 
is a wide variation in antibiotic prescription patterns within 
and between different cities within a given country.61,79–84
Antibiotics are also over-prescribed in ambulatory care, 
especially for respiratory tract infections.85 When primary care 
physicians are asked their reasons for prescribing antibiotics for 
upper respiratory tract infections, they cite clinical factors (dura-
tion of the illness, probability of poor results) and nonclinical 
factors (patient satisfaction, time savings for the clinic). The 
physician’s practice style can be correlated with duration of the 
visit and whether an antibiotic is prescribed; physicians with 
shorter visit times are more likely to prescribe antibiotics.86
At the same time, some studies suggest that more than half 
of antibiotic prescriptions are inappropriate.87,88 In Mexico, 
recent studies have documented that between 60% to 80% 
of the patients were with upper respiratory tract infections 
received inappropriate prescriptions of antibiotics.12
Physicians resist changing their behavior, and maintain-
ing antibiotic prescription models against patient or family 
member pressure represents a particular challenge.16,19,57,89,91 
One study suggests that patients want an antibiotic because 
of a mistaken belief that it is the best treatment for pain.92
On the second broad inﬂ  uence, patient demand, we ﬁ  nd 
that treatment compliance depends on the characteristics of 
the patient, the illness, and social and family environment, 
and on the health care system and health care professionals, 
including physicians and pharmacists. In addition, other 
factors such as patient age, sex, ethnicity, level of education, 
economic level, hygiene, and community facilities all affect 
the appropriateness of the treatment and patient compli-
ance.61,93 People use antibiotics with excessive familiarity, 
lack of concern, and conﬁ  dence; they self-medicate because 
antibiotics are available without professional control; and 
patients believe that antibiotics are more effective than any 
other types of medicines.62,89,94 In some countries, including in 
developed countries, antibiotics are freely available and can 
be bought without a prescription (even if this is prohibited by 
law) at sidewalk stands from vendors who know little or noth-
ing about dosage, indications, or contraindications.22,95,96
When antibiotics are used incorrectly – for too short a 
time, at too low a dose, too low a frequency, or for the wrong 
illness – bacteria and other microorganisms are more likely 
to adapt and replicate rather than die.90
Furthermore, an association has been found between 
the patient’s lack of participation in the physician visit 
and the patient’s poor understanding of the medications 
prescribed.80
Macro-level determinants include overcrowding, poor 
sanitation, and a lack of observance of recommended sanitary 
procedures, so that propagation of pathogenic bacterial 
agents is increased, leading to increasing illness rates, thus 
creating a greater need for antibiotic use.4 Antibiotic use is 
also inﬂ  uenced by the interaction between the knowledge and 
expectations of prescriber and patient, economic incentives, 
and characteristics of the health care system and the regulatory 
system.90 The key determinant is related to government policy 
on hospital ﬁ  nancing.16
The cultural context of antibiotic use also plays an 
important role. Expectations of medical care are affected by 
the patient’s socioeconomic status; patient satisfaction has 
been observed to decrease slightly with increased income.97 
In Hungary, lower socioeconomic status has been found to 
be a determinant in antibiotic use.98
A particularly disturbing aspect of the growth of resis-
tance is the long term addition of antibiotics, at subtherapeutic 
concentrations, to food and water and as growth promoters in 
animal feed, such as poultry feed.99,100 Some resistant bacteria 
found in animals are transmitted to humans, mainly in meat 
and other foods of animal origin, or through direct contact 
with animals as they are being raised, which may have serious 
consequences for children and the elderly.20,55,101,102
Studies in different cities in the UK and US have shown 
an association between the use of antibiotics in animal feed 
and antibiotic resistance.20,102
In the twentieth century, the use of antibiotics to treat 
bacterial illnesses in animals–including fish–and plants 
also increased. At least 17 classes of antibiotic agents 
have been approved as growth promoters in the US. These 
include tetracyclines, penicillins, macrolides, lincomycin 
(a clindamycin analog), and virginiamycin. The precise number 
of antibiotic agents used in agriculture is unknown.63,101–103Infection and Drug Resistance 2009:2 7
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Transfer of resistant bacteria from animal feed to humans 
is most evident in human pathogenic bacteria that have animal 
feed sources, such as Campylobacter, of which chickens and 
ducks are a reservoir, and Salmonella, found in chicken, 
pigs, cattle, and ducks. Campylobacter species cause mild 
to moderate infections and occasionally severe infections, 
especially in children, the elderly, and immunocompromised 
persons. A 1999 University of Iowa study found multidrug-
resistant and cephalosporin-resistant human, porcine, and 
bovine Salmonella isolates in the same geographic region. 
Although there is much heterogeneity between animal feed, 
meat, poultry and human samples, they do provide evidence 
of the spread of gentamicin-resistant enterococci from 
animals to humans through food.55,61
Antibiotics have also been used extensively for treatment 
and prevention of bacterial diseases in crops, fruit trees, and 
ornamental plants.61 In 1996, 300,000 pounds of streptomycin 
and oxytetracycline were aerosolized to treat apples and pears 
prophylactically against infections.34
Ingestion of substandard, counterfeit or inadequately 
stored antibiotics or of subtherapeutic doses leads to inef-
fective or incomplete treatment which increases the selective 
pressure on resistant strains. Metabolites and excess drug are 
excreted, and can enter the environment through inadequately 
treated waste or unhygienic sanitary conditions. The most 
direct route by which antibiotics from human waste enter 
rivers is through wastewater treatment outﬂ  ows. Hospitals 
may also send antibiotics and resistant bacteria to landﬁ  lls, 
from which they enter the water. These antibiotics are non-
biodegradable whether in sediment or in water.65,103,104
Paradoxically, chlorination of drinking water and 
wastewater substantially raises the proportions of antibiotic-
resistant bacteria even though it reduces initial counts.104
Some antibiotics are completely stable in liquid, and some 
are tolerant to heat. For example, small quantities of neomycin 
in egg are quite tolerant to normal cooking processes.61
Compounds such as household disinfectants and other 
antibacterial agents can also inﬂ  uence antibiotic resistance. The 
increase in the use of these agents has caused dramatic changes 
in environmental ﬂ  ora, because of antibiotic resistance.61
A thorough consideration of the theory of evolution and 
the microorganism theory of infectious diseases leads to the 
conclusion that excessive use of antibiotics in any ecological 
niche will produce harmful effects on human health in the 
same niche, as well as in niches nearby and farther away.105
The last group of determinants of antibiotic resis-
tance is related to dosing variations and the use of poor 
pharmacodynamic principles. One of the later approaches 
of antimicrobial resistance separates genetic resistance into 
types: acquired and de novo. Acquired resistance involves 
genes system that move into pathogen population and external 
source and de novo resistance often develops in a gradual, 
stepwise manner, usually from the accumulation of mutation 
that individually lower susceptibility by modest increments. 
In principle, blocking the growth of mutants subpopulations 
should lead to resistance more rapidly than ones that do not 
even though the regimens may equally effective at curing 
disease. The problem is to identify mutant-prone regimens 
prior to widespread clinical use.74–77
The mutant selection window is antimicrobial concentra-
tion range extending from the minimal concentration required 
to block the growth of wild-type bacteria up to that required 
to inhibit the growth of the least susceptible, single-step 
mutant. Since window dimensions are characteristic of each 
pathogen–antimicrobial combination, they can be linked 
with antimicrobial pharmacokinetics to rank compounds 
and dosing regimens in terms of their propensity to enrich 
mutant fractions of bacterial populations. The described 
theory suggests that for situations in which antimicrobial 
concentrations cannot be kept above window, restricting 
the enrichment mutants requires combination therapy. It 
might provide a rationale for deciding whether a compound 
(antibiotic) should be administered as part of a combination 
regimen rather than being used alone. The described hypoth-
esis is still awaiting in vivo validation.74–77
Consequences of antibiotic resistance
Among the US population of more than 300 million 
Americans, there are 160 million antibiotic prescriptions 
for a total of 23 million kg of antibiotics per year. In 1992, 
18% of the total antibacterial medicines prescribed in the US 
were for respiratory illnesses. S. pneumoniae is resistant to 
various drugs.62,106
Resistance to penicillin, cephalosporins and other 
β-lactam antibiotics has increased the use of erythromycin and 
new macrolides such as azithromycin and clarithromycin.106 
For this reason bacterial infections resistant to antibiotics are 
becoming increasingly common in clinical settings.107
Some countries have already given ofﬁ  cial recognition to 
the effects of increasing bacterial antibiotic resistance on public 
health. Bacterial antibiotic resistance is a serious problem world-
wide, with implications for morbidity, mortality and health care 
in hospitals and in the community.34,64,103,107,108 An association 
has been demonstrated between initially inappropriate antibiotic 
treatments and increased mortality, because resistant organisms 
are more difﬁ  cult to treat and almost impossible to eradicate Infection and Drug Resistance 2009:2 8
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in some patients.104 For this reason, there is growing concern 
that resistant organisms might arise that cannot be effectively 
treated with available antibiotic therapies.103
Research has been shown that resistance often leads to a 
delay in the administration of a microbiologically effective 
therapy, a chain of events which has been associated with 
detrimental outcomes. The majority of published studies 
have shown an association between antibiotic resistance 
and adverse results in the order of a 1.3 to 2 times increase 
in mortality, morbidity, and costs for patient with resistant 
infections, compared with susceptible infections.31,109
Individuals receiving antibiotics at therapeutic doses 
undergo changes in their normal intestinal, upper respiratory 
and genitourinary ﬂ  ora. In some cases a superadded infection 
may arise as a result of these changes. The broader the effect 
of an antibiotic, the more it alters the normal microﬂ  ora, 
and the greater the probability that a single microorganism 
will predominate, invade the host and produce infection.21 
Hospital-acquired infections are not only difﬁ  cult to treat, but 
also signiﬁ  cantly delay the patient’s discharge from hospital 
and signiﬁ  cantly increase the cost of treatment. Moreover, 
when the patient is discharged from hospital, health care 
workers and visitors may become carriers facilitating the 
spread of resistant microorganisms to the community.104,110
Another problem related to antibiotic resistance is the 
enormous cost to the patient and the health care system. In the 
US the annual cost of treating antibiotic-resistant infections 
has been calculated at more than US$4 billion.103
As drug-resistance to older, and in general cheaper, 
antibiotics becomes more common, a newer, more expen-
sive, broad spectrum drug or combination therapy may be 
required. The prescriber’s concern about antibiotic resistance 
may however lead to an empirical choice of newer, more 
potent drugs or combinations of drugs for fear that a delay 
in waiting to identify the bacteria and assess its sensitivity 
might increase morbidity or mortality.105 These agents are 
usually more expensive, and people with lower incomes can 
afford them even less. The newer drugs are also more likely 
to have harmful effects on protective microﬂ  ora and may even 
be toxic or less effective.31,109
In fact, studies in the medical literature have shown con-
clusively that patients infected with drug-resistant organisms 
are more likely to require hospitalization, to have a longer 
hospital stay, and have an increased probability of dying.5
Other consequences for patients that must be considered 
include the long term effects on future health of having 
a resistant infection, increased time off work, being way 
from family due to longer hospitalization and subsequent 
recuperation, and the emotional effects of having a resistant 
infection.59
Alternatives to antibiotic resistance
The indiscriminate use of antibiotics to treat diseases in 
humans, and their increasing use in the agricultural industry 
are important points. As already mentioned, up to 50% of 
antibiotic use in humans may be questionable and up to 80% 
of agricultural use may be unnecessary.68
The incidence of multidrug-resistant pathogenic bacteria is 
on the rise. More than 70% of the bacterial species that cause 
these infections are likely to be resistant to at least one com-
monly used antibiotic.58 This trend will continue as long as the 
resistance problem remains unchecked. There are some actions 
that are widely agreed to be essential areas of general consensus 
for recommended action.7,20,73,85,90,94,110–119 Local governments 
should establish policies for the elaboration of national and 
regional guidelines for infection control based on surveillance 
data on resistance and reinforce the general health laws in the 
dispensing of antibiotics at all levels as well as eliminate ﬁ  nan-
cial incentives that promote misuse of antibiotics.
The promotion of communication between government, 
academic institutions, and the pharmaceutical industry should 
be reinforced and mutual collaboration must be promoted. 
Academic institutions should periodically and systematically 
evaluate health-related curriculums for continuing education 
for veterinarians, physicians, physician extenders, pharmacists, 
and nurses to ensure that rational use of antibiotics is taught.
Health institutions should systematically and continu-
ally evaluate antibiotic prescriptions to ensure the rational 
use of antibiotics. Continuing education programs about the 
rational use of antibiotic for all health professional should 
be institutionalized. Among physicians, health institution 
policies should include the prudent promotion of antibiotics 
prescribing; promote improvements in hygiene; improve 
patient care; promote appropriate treatment selection; 
identify pathogens and resistant pathogens.
Hospitals should establish infection control committees, 
drug therapy committees, guidelines for appropriate use of 
antibiotics based on evidence; produce pharmacy reports 
based on deﬁ  ned daily doses; establish a list of essential drugs; 
educate staff about problems related to antibiotics use.
Community pharmacies should avoid the practice of 
“prescribing” (particularly in developing countries) and 
dispensing antibiotic without medical prescriptions.12
Physicians and pharmacists should discuss with 
patients the proper use of antibiotics and the individual and 
environmental consequences of their misuse.Infection and Drug Resistance 2009:2 9
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Veterinarians should minimize antibiotic use in animals, 
work to improve hygiene on farms, and use other alternatives 
to promote animal growth. Local governments should regulate 
antibiotic prescribing in animals and their use in soils; restrict 
the use of antibiotics as growth promoters; reduce the need 
for prophylactic and therapeutic use of antibiotics; improve 
vaccination programs and farm hygiene.
All local governments, health care and academic 
institutions, health professionals and individuals should 
work together to improve antibiotic resistance surveillance 
through local surveillance networks; recruit participants to 
the networks; support reference laboratories and the World 
Health Organization programs; monitor resistance in food 
animals; and monitor human populations.
Research projects at all levels should include risk-beneﬁ  t 
analysis of the use of growth promotants, environmental 
impacts, and processing and distribution methods for food.
In the pharmaceutical industry, increased research and 
development on new and cost-effective antibiotics is needed. 
More research has to be done on the measurement and poten-
tial use of mutant selection window.74–77
Conclusions
Analysis of the published literature showed that the main 
determinants of antibiotic resistance are irrational use of anti-
biotic drugs in humans and animal species, insufﬁ  cient patient 
education when antibiotics are prescribed, lack of guidelines for 
treatment and control of infection in hospitals, lack of awareness 
and relevant scientiﬁ  c information for physicians prescribing 
antibiotics, and lack of ofﬁ  cial government policy on the rational 
use of antibiotics in the public and private sectors. It is therefore 
necessary that every country take proper measures to control 
these determinants in order to check antibiotic resistance.
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